Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPHiA GENETICS files a resale prospectus to register 75,000 ordinary shares issuable upon exercise of a warrant previously issued to Perceptive Credit Holdings IV, LP. The Second Amendment warrant carries an exercise price of $5.1829 per share and is exercisable for cash until 5:00 p.m. Eastern on January 23, 2036.
The company will not receive proceeds from secondary sales by the selling shareholder; however, if the Second Amendment warrants are exercised in full the company could receive up to $388,717.50, which it says would be used for working capital and general corporate purposes. Shares outstanding were 89,321,220 ordinary shares as of December 31, 2025.
SOPHiA GENETICS files an F-3 to register up to 75,000 ordinary shares for resale by a selling shareholder. These shares are issuable upon exercise of a warrant (the "Second Amendment warrant shares") with an exercise price of
We will not receive proceeds from resale by the selling shareholder; however, we may receive up to
SOPHiA GENETICS has filed its annual Form 20-F for the year ended December 31, 2025, presenting IFRS-based consolidated financial statements and extensive risk disclosures. The company had 68,486,338 ordinary shares outstanding as of year-end.
The report describes the SOPHiA DDM Platform, a cloud-based multimodal data analytics solution used across oncology, rare and infectious diseases, cardiology, neurology and other areas. Management highlights numerous forward-looking statements and cautions that actual results may differ materially due to detailed risk factors.
Key risks include challenges expanding platform features and data modalities, dependence on sales and marketing execution and strategic relationships, uncertain reimbursement and market adoption, intense competition, ongoing net losses with no assurance of future profitability, heavy reliance on third parties and key personnel, cybersecurity and data privacy threats, and significant regulatory and IVD approval requirements in the U.S. and Europe.
SOPHiA GENETICS reported strong 2025 revenue growth but remains loss-making. Fourth-quarter revenue reached
The company recorded a 2025 IFRS net loss of
For 2026, SOPHiA GENETICS guides to revenue between
Zhenyu Xu submitted a Rule 144 notice reporting proposed sales of Common stock. The filing lists recent 10b5-1 sales by Zhenyu Xu, including sales of 4,000 shares on
SOPH submitted a Rule 144 notice for the proposed sale of 684 restricted stock units by the issuer, dated
Sophic Biosciences reports a proposed sale of restricted stock units by an affiliate. The filing lists 760 restricted stock units proposed for sale on
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 reporting proposed dispositions of Common shares and listing recent 10b5-1 sales executed by Philippe Menu.
The excerpt shows multiple 10b5-1 sales: 5,000 shares on
SOPH affiliate reported proposed and recent insider sales of common stock and restricted stock units. The notice lists a proposed sale of 380 restricted stock units dated
Balderton Capital VI, S.L.P. has updated its ownership disclosure for Sophia Genetics SA, reporting beneficial ownership of 3,301,240 Ordinary Shares of CHF 0.05 per share. These shares are held of record by BCVI, with BCVI Sarl as managing general partner.
The stake represents 4.9% of the outstanding Ordinary Shares, based on 67,579,560 shares outstanding as of June 30, 2025, as reported in a prospectus on Form 424(b)(5). Balderton reports shared voting and dispositive power over all 3,301,240 shares and no sole voting or dispositive power, and each reporting person disclaims beneficial ownership beyond its pecuniary interest.